Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hereditary angioedema patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…
Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country,…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas),…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Americas pharmaceutical markets (Argentina, Canada, Chile, Colombia, and Peru…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Middle East & Africa pharmaceutical markets (Egypt, Nigeria, Saudi Arabia, and…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Asia-Pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pemphigus vulgaris patient population covering 171 countries and…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…
Clarivate Epidemiology's coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus…
As the number of gene therapy approvals rises, novel approaches to value assessment and reimbursement schemes for these innovative, high-cost treatments are rapidly gaining importance. Developers…